- According to various reports, the FDA’s neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately.
- Dunn presided over the controversial approval of Biogen Inc’s BIIB Alzheimer’s disease treatment, Aduhelm (aducanumab).
- Dunn, 53, is retiring from the agency to “explore other opportunities,” according to an internal FDA email. Dunn notified agency officials Friday, according to a person with knowledge of the situation.
- Reata Pharmaceuticals Inc RETA shares are falling in reaction to the news as its marketing application seeking approval for omaveloxolone for Friedreich’s ataxia is due on 28 February.
- The FDA has already postponed the application after the company submitted additional data.
- Friedreich ataxia is a rare inherited disease that causes progressive damage to your nervous system and movement problems.
- Nerve fibers in your spinal cord and peripheral nerves degenerate, becoming thinner.
- Price Action: RETA shares are down 35.7% at $28.61 on the last check Monday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.